Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-08-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第二届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 2nd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and voting results on board matters such as director resignations and nominations, and the proposal to convene a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is an official announcement of board decisions and changes in board composition, which fits the category of Board/Management Information (MANG). The document length is short (1399 characters), and it is not a report or presentation but a meeting resolution announcement.
2017-08-20 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle raised funds for cash management, specifically purchasing bank wealth management products. It details the amounts, dates, risk analysis, and control measures related to these investments. The document is relatively short (3103 characters) and focuses on a specific financing activity rather than presenting comprehensive financial statements or results. It is not an annual or interim report, nor an earnings release or management discussion. It is an update on the company's capital usage and financing activities related to raised funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-08-15 Chinese
关于公司涉及诉讼事项的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding ongoing litigation matters involving the company. It details the parties involved, the nature of the lawsuits, and the potential impact on the company's profits. The document includes references to court cases, legal claims, and related background information. There are no financial statements, earnings data, or management discussion of financial results. The document is clearly a legal proceedings update rather than a financial report or other filing type. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 3766 characters, which is consistent with a detailed announcement but not a full financial report.
2017-08-08 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the progress of using idle raised funds for cash management, specifically detailing the redemption of bank wealth management products purchased with idle raised funds. It includes investment risk analysis, risk control measures, impact on company operations, and a summary of recent transactions involving raised funds. The document is relatively short (2960 characters) and focuses on disclosing specific financial management activities rather than providing comprehensive financial statements or full financial performance reports. It is not an annual or interim report, earnings release, or audit report. It is also not a regulatory certification or officer attestation. The content fits the category of a regulatory announcement about the use of raised funds and related financial activities, which aligns best with the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-08-06 Chinese
2017年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2017, indicating expected profit decline and reasons for the change. It explicitly states that the financial data is preliminary, unaudited, and will be detailed in the upcoming half-year report. The document is short (835 characters) and serves as an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements or substantive data. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. H1 2017
2017-07-13 Chinese
国浩律师（杭州）事务所关于公司实际控制人丁列明增持公司股份的法律意见书
Major Shareholding Notification Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the increase in shareholding by the company's actual controller, Ding Lieming, in Betta Pharmaceuticals Co., Ltd. It details the legal compliance, procedures, and qualifications related to the shareholding increase. The document is not a financial report, earnings release, or management discussion. It is a legal opinion specifically about a shareholding increase event. This fits the category of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is about the legal opinion on the shareholding increase, which is part of the disclosure for such a change. The document length is about 4885 characters, which is sufficient for a detailed legal opinion. Therefore, the best classification is MRQ with high confidence.
2017-07-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.